16 slides from Integral Diagnostics's shareholder meeting presentation, Oct 30, 2020
Slide 1: AGM Address by the Chair and Managing Director and CEO
T | +61 3 5339 0704 E | info@integraldiagnostics.com.au Suite 9.02, level 9, 45 William St Melbourne Vic 3000 www.integraldiagnostics.com.au AGM Address by the Chair and Managing Director and CEO AGM Presentation 30 October 2020, Melbourne Attached are copies of the address and presentation to be gi
Slide 2: Chair Address
Integral Diagnostics Limited 2020 Annual General Meeting Chair Address I would like to commence with two key reflections. The first a reflection on this being Integral Diagnostics’ fifth AGM and anniversary from listing on the ASX on 21 October 2015 with 44 clinics, 770 staff and a market cap of $27
Slide 3: Q1 FY21 Revenue Information
Q1 FY21 Revenue Information We commenced this current financial year with Stage 4 restrictions operating in Melbourne and Stage 3 for regional Victoria and Auckland. Overall Integral Diagnostics’ operations has delivered organic revenue growth of 4.2% in the first quarter of this financial year comp
Slide 4: Managing Director and CEO Presentation
Integral Diagnostics Limited 2020 Annual General Meeting Managing Director and CEO Presentation
Slide 5: Strong, Consistent Performance
STRONG, CONSISTENT PERFORMANCE IDX has performed well for several years - delivering strong, consistent growth in revenue and earnings Revenue ($m) Operating EBITDA ($m) 18.7% 20.9% 274.1 64.1 230.9 53 189.4 179.7 167.8 38.1 34.9 33.5 FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY18 FY19 FY20 Operating NPAT
Slide 6: Delivering on Our Values in FY20
DELIVERING ON OUR VALUES IN FY20 Your company delivered strong results across all our values in FY20, despite significant COVID-19 impacts in the first months of the pandemic. Doctors and staff stepped up to the new challenges with strong leadership, clinical acumen, dedication and commitment. We al
Slide 7: Share Price Performance
SHARE PRICE PERFORMANCE The IDX share price reflects our strong, consistent earnings growth ASX IDX $5.00 9,500 $4.50 8,500 $4.00 $3.50 7,500 $3.00 6,500 $2.50 5,500 $2.00 $1.50 4,500 $1.00 3,500 $0.50 2,500 $0.00 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 Apr-18 Oct-18 Apr-19 Oct-19 Apr-20 ASX IDX Source:
Slide 8: IDX Operates in High Growth Geographic Markets
IDX OPERATES IN HIGH GROWTH GEOGRAPHIC MARKETS Total IDX Geographic Western Victoria Queensland New Zealand Queensland Market Australia Ballarat, Geelong, Sunshine Gold Coast, South West Warrnambool Coast, Core markets Toowoomba Western Auckland and outer Rockhampton and Mackay Australia western are
Slide 9: Strategy – Good Medicine is Still Good Business
STRATEGY – GOOD MEDICINE IS STILL GOOD BUSINESS Strategy 1 Grow existing business and margin 2 Strategic acquisitions Accelerate use Drive organic of digital and Nurture and Drivers of AI technology Drive our growth, develop strategy to improve the environmental, business culture and Evaluate furthe
Slide 10: Diagnostic Imaging Industry COVID-19 Impact: Australia
DIAGNOSTIC IMAGING (DI) INDUSTRY COVID-19 IMPACT: AUSTRALIA Industry growth rates in Australia were significantly impacted by COVID-19 in March and June 2020 quarters Industry growth 12 month rolling growth rate by services 12 month rolling growth rate by benefits -- Long Term Average 4.7% (2020 (1.
Slide 11: IDX COVID-19 Revenue Impact
IDX COVID-19 REVENUE IMPACT FY21 First Quarter Operations Delivered organic revenue growth* of 4.2% in FY21Q1 vs PCP • Solid revenue growth in all regions except Victoria • Impact of the second wave significantly less severe than initial pandemic impact (in April and May) • NZ practices have not bee
Slide 12: Regulatory Environment
REGULATORY ENVIRONMENT IDX plays a leadership role in the industry. Healthcare payors in Australia and NZ continue to recognize the preventative benefits of DI in providing quality patient care and reducing unnecessary healthcare cost Australia • Medicare DI indexation introduced on 1 July 2020 • Br
Slide 13: Appointment of Chief Operating Officer
APPOINTMENT OF CHIEF OPERATING OFFICER IDX has appointed a COO to help manage the extensive growth in company operations Internal Appointment 20 years of industry experience – with IDX, SKG (Sonic’s WA imaging business), and Qscan Currently IDX General Manager for Western Australia • Driven the grow
Slide 14: Artificial Intelligence in Diagnostic Imaging: Improving Patient Outcomes
ARTIFICIAL INTELLIGENCE (AI) IN DIAGNOSTIC IMAGING: IMPROVING PATIENT OUTCOMES IDX currently invests in 4 AI algorithms, with 2 more in testing • Current 4 limited to Head, Neck and Chest CT’s in selected IDX business units • Continue to grow AI capabilities as new applications are proven to benefit
Slide 15: IDX Senior Leadership Team
IDX SENIOR LEADERSHIP TEAM COO appointment augments the IDX Senior Leadership Team, consistent with the extensive growth of the business Paul McCrow Dr Ian Kadish Anne Lockwood Chief Operating Officer Managing Director Chief Financial and and Chief Commercial Officer MBA, B App Sc – Executive Office
Slide 16: FY21 Key Priorities and Focus
FY21 KEY PRIORITIES AND FOCUS FY21 Priorities and Focus • Manage ongoing impacts of COVID-19 Drive organic growth, • Integrate Ascot Radiology business integration and further efficiency • Promote benefits of MRI and PET technologies so they’re widely understood and recognised by patients, gains pay